👉👉👉Amazing talk at the intersection of hemepath & leukemia and chance for a quick group photo afterward - by our own world-renowned faculty speaker Dr .Sanam Loghavi, MD صنم لغوی 🔬🧬 in MD Anderson Cancer Center Hematology Grand Rounds this AM !!! #leusm #hemepath #endcancer | Heme Reports

👉👉👉Wonderful to get to spend some time with our friend & colleague @CRausch who is back in town this weekend ! Kayleigh Marx, PharmD, BCOP Tapan Kadia | #leusm

👉👉👉Just out in AmericanJournalofHematology - our group’s new paper led by .Tapan Kadia & Hagop Kantarjian,MD || Ph2 study Results CPX-351+VEN for patients w/ R/R AML (n=33;44%2nd Salvage Tx or later;30%prior SCT:: ORR=46% w/CRc 39%) #leusm #endcancer | onlinelibrary.wiley.com/doi/10.1002/aj… | Sanam Loghavi, MD صنم لغوی 🔬🧬

#EHA25 #EHA2025 || So awesome to see our leading young superstar MDs Dr Wei Ying Jen with Dr Alex Bazinet at the posters and senior author Tapan Kadia || 🙌 #endcancer #leusm

👉Leukemia team together MD Anderson Cancer Center today! Naveen Pemmaraju, MD Wei Ying Jen Tapan Kadia vanthana bharathi Roberta Azevedo 🙌

#Myeloma Paper of the Day: Phase 2 study of dara/thal/dex in relapsed and/or refractory MM finds median PFS 16 months (9.4 if thal/len/pom refractory), ORR 82% (64% VGPR or better, 25% CR or better, 13% sCR), median DOR 19 mos, median OS 32.5 mos: pubmed.ncbi.nlm.nih.gov/40527888/. #mmsm

Myeloma Paper of the Day, June 18th, suggested by Robert Orlowski (Robert Z. Orlowski) MD Anderson Cancer Center Chng Wee Joo Wei Ying Jen oncodaily.com/science/myelom… #OncoDaily #Oncology #Cancer #Health #Medicine #MedTwitter #MedEd #MedOnc #MedNews #MM #RRMM #Myeloma #Daratumumab #Thalidomide

👉👉We report case series of 6 patients with T-ALL/LBL who developed rhabdomyolysis after receiving nelarabine 👉 Check CK if pt develops myalgia, unexplained rise in creatinine while on nelarabine Mehmet S Uyanik, MD Hagop Kantarjian,MD tandfonline.com/doi/full/10.10…

👉Here is an updated version of the Table which I initially posted post ASH2024. 👉Now Updated with EHA 2025 data including updated FLAIR, CLL13, CAPTIVATE trials. #CLL

👉👉👉Leukemia Team together right after my annual #BPDCN Update Leukemia Wed noon grand rounds talk hosted by Dr Guillermo Garcia-Manero ! Naveen Pemmaraju, MD #endcancer | Danielle Hammond, MD Hagop Kantarjian,MD Nitin Jain Sanam Loghavi, MD صنم لغوی 🔬🧬 Kamran Mirza MD PhD - کامران مرزا Marina Konopleva Muzaffar Qazilbash Fadi Haddad, MD Jayastu Senapati 🙌

For the love of God😡There has to be a better way to utilize all this fancy #AI & make ASH abstract submissions more efficient (for $85 a pop). Takes ~ hour ⏳to just add authors!!! 🤦🏻‍♀️ & here I am fearing AI may make my job obsolete… 😬not in this lifetime 😴

👉👉👉Important new paper led by Dr Sankalp Arora, MD & Prof Naval Daver, M.D. just out in ACS Journal Cancer #FLT3TKD #NPM1 for patient with AML #leusm #endcancer Sanam Loghavi, MD صنم لغوی 🔬🧬 Ghayas Issa Nicholas Short MD Tapan Kadia Guillermo Garcia-Manero Hagop Kantarjian,MD acsjournals.onlinelibrary.wiley.com/doi/10.1002/cn…

We report incidence of NPM1-wildtype relapses in pts treated with VEN-based frontline tx in AML.   🔴Overall, absolute # of relapses in NPM1 AML after VEN is ⬇️  🔴the fraction of NPM1-wildtype relapses ⬆️ with the⬆️ intensity of chemo backbone added to VEN.  🔴 NPM1 wildtype

👉👉👉Wonderful to meet up with the future leaders of leukemia research ! Naveen Pemmaraju, MD w/ Dr Alex Bazinet , Dr Wei Ying Jen & Dr Jen Marvin-Peek, MD | #leusm #MPNSM #BPDCN | #endcancer

👉👉👉Major new paper 📑 👉just out in BJH led by Dr .Wei Ying Jen & Dr .Tapan Kadia MD Anderson Cancer Center 📣 #MECOM fusion partner & bone marrow blast % influence outcomes of patients w/#MECOM -rearranged AML | Sanam Loghavi, MD صنم لغوی 🔬🧬 onlinelibrary.wiley.com/doi/10.1111/bj… #endcancer #leusm #MECOM

👉👉👉Our group’s new paper 📝 led by Dr C DiNardo & Dr K Bhalla || #Omacetaxine + VEN in patients with R/R MDS/AML with #RUNX1 mutation | Blood Journals Portfolio Guillermo Garcia-Manero Sanam Loghavi, MD صنم لغوی 🔬🧬 Tapan Kadia Naval Daver, M.D. sciencedirect.com/science/articl…

👉Delighted to share case series of pts with ABL class fusion ALL who received TKI with frontline Rx for ALL.Notably all 9 patients remain in CR1. 👉 Highlights need for early identification of kinase sensitive fusion and initiation of TKI Julie Braish MD Anderson Cancer Center Link👇

(1/10) How do diverse leukemia mutations converge on the same molecular program? In our new study Cell,the Riback Lab - Cellular Physical Chemistry Group and Peggy Goodell show that disparate mutations rewire shared protein networks to form nuclear condensates called coordinating bodies (C-bodies).🫧

👉👉 Case report of a patient with FIP1L1-PDGFRA fusion with significant extra medullary involvement with cord compression 👉10+ year remission with single agent imatinib without any chemotherapy indicating exquisite sensitivity of this fusion to imatinib tandfonline.com/eprint/2IGUUBX…

👉👉👉Happy to share our group’s new report in #MPNSM field led by Dr .vanthana bharathi & Dr Nitin Jain #FIP1L1 - #PDGFRA Sangeetha Venugopal MD,MS tandfonline.com/doi/full/10.10…